Discover how pharmaceutical companies use authorized generics to maintain revenue and fight competition after patent expiration. Learn the difference between authorized and traditional generics.
read more
Tentative approval from the FDA means your generic drug is ready to sell - but you can't launch yet due to patents. Learn how litigation, timing, and paperwork determine whether you win market entry or lose millions.
read more
Paragraph IV certifications let generic drug makers challenge brand patents before launching. This legal tool under the Hatch-Waxman Act has saved U.S. consumers over $2 trillion since 1984 by speeding up generic access.
read more